Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Decision Resources
September 18, 2009 24 Pages - SKU: DECR2444609
|
|
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations-such as
creating more entrepreneurial environments modeled upon biotech companies-increase their productivity?
Many major companies are reorganizing the research branches of their businesses and fi nding
creative ways to partner with biotech companies and with each other to access or acquire promising
technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations,
generics competition, and other industry pressures.
Questions Answered in This Report
- In recent years, drug developers have invested heavily in various R&D technologies. Is this investment
increasing R&D productivity? What technology strategies are most promising? What
new approaches are pharmaceutical companies using to access enabling technologies for drug
discovery?
- Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
What steps are leading companies taking to change R&D? What structures and strategies
have already been implemented within Big Pharma R&D organizations? Can pharmaceutical
companies replicate the innovation of biotech companies by reforming R&D?
- Biotech companies are an important source of novel technologies and drug candidates. How do acquisitions
of and collaborations with biotech companies fi t into Big Pharma's R&D strategies?
How can companies use business development activities to build up technological capabilities
and pipelines?
- Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.
Which companies have recently formed innovative partnerships that include early-stage
development? What are the key features of these arrangements? How do these ventures meet
the strategic needs of both partners?
Scope
- Technology strategies: Use of high-throughput technologies and R&D productivity, biologics
platforms, pharma-pharma ventures for enabling technology development.
- Organizational structures and strategies: Restructuring R&D, emulating biotech, case
studies of R&D reorganization.
- Building R&D through business development: M&As, collaborations, R&D strategies.
- Pharma-pharma partnering: Strategic alliances among Big Pharma companies, Phase I
codevelopment collaboration, therapeutic area joint venture.
- Outsourcing R&D: China, India, potential advantages and disadvantages.
- Outlook for pharmaceutical R&D: Changing business models, personalized medicine,
pursuing novel targets, collaboration, high-throughput strategies, translational medicine.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Technology Strategies—Will They Pay Off?
- The Industrialization of Drug Discovery
- Biologics Platforms
- Enlight Biosciences: Big Pharma’s Technology Collaboration
- Organizational Structures and Strategies
- GlaxoSmithKline
- Novartis
- Pfi zer
- Sanofi -Aventis
- Building R&D Through Business Development
- Pharma-Pharma Partnering
- AstraZeneca and Merck: Early-Stage Development for Cancer
- GlaxoSmithKline and Pfi zer: A Joint Venture for HIV
- Moving R&D to China and India
- Outlook for Pharmaceutical R&D
- Tables
- 1. Top-Selling Biologic Drugs
- 2. Bristol-Myers Squibb’s “String of Pearls” Deals
- 3. GlaxoSmithKline/Pfi zer HIV Joint Venture Portfolio
- Figures
- 1. Combined R&D Expense vs. New Molecular Entity Approvals for 15 Top Pharmaceutical Companies, 2000-2008
- 2. Business Model for Enlight Biosciences
- 3. Simplifi ed Scheme of the Mechanisms of Action of MK-2206 and AZD-6244
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
